Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 12/20 | 0.75 |
| ▸ | GCGR | P47871 | 8/20 | 0.71 |
| ▸ | GIPR | P48546 | 5/20 | 0.70 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29568059 | 1.00 | GLP1R (0.75) | GLP1RGCGRGIPRPTH1RCXCR4 | |
| SCHEMBL29376189 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29399148 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29359393 | 0.99 | GLP1R (0.76) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL31759052 | 0.98 | GLP1R (0.75) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL30874225 | 0.97 | GLP1R (0.73) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL29395085 | 0.96 | GLP1R (0.73) | GLP1RGCGRGIPRCXCR4 | |
| SCHEMBL30473776 | 0.96 | GLP1R (0.75) | GLP1RGCGRGIPR | |
| SCHEMBL30473781 | 0.96 | GLP1R (0.73) | GLP1RGCGRGIPRPTH1R | |
| SCHEMBL30473787 | 0.96 | GLP1R (0.75) | GLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698209-A1 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | The Board of Trustees of The Leland Stanford Junior University (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260048101-A1 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | AMYLYX PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4646220-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | Bioage Labs, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250195855-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2025-06-19 | — | — | US | disclosed |
| US-20240398884-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. | 2024-11-07 | — | — | US | disclosed |
| WO-2024220962-A1 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240307501-A1 | TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDE | EIGER BIOPHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024148104-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4358996-A1 | TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDE | Eiger Biopharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4233842-A2 | AVEXITIDE FOR THE TREATMENT OF HYPERINSULINEMIC HYPOGLYCEMIA | Eiger Biopharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022271753-A1 | TREATMENT OF CONGENITAL HYPERINSULINISM WITH AVEXITIDE | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220288150-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-15 | — | — | US | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048101-A1 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | GLP1R, GIPR, GCGR | GLP1R 1/4885GCGR 3/4885GIPR 2/4885 |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | APLNR, GLP1R, GIPR | GLP1R 2/4885GCGR 4/4885GIPR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.